Cargando…
Metabolic Plasticity in Melanoma Progression and Response to Oncogene Targeted Therapies
SIMPLE SUMMARY: Targeted anti-cancer therapies have revolutionised melanoma patient care; however, cures remain uncommon due to acquired drug resistance that results in disease relapse. Recent insights from the clinic and experimental settings have identified a key role for metabolic plasticity, def...
Autores principales: | Alkaraki, Arwa, McArthur, Grant A., Sheppard, Karen E., Smith, Lorey K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8616485/ https://www.ncbi.nlm.nih.gov/pubmed/34830962 http://dx.doi.org/10.3390/cancers13225810 |
Ejemplares similares
-
The therapeutic potential of targeting minimal residual disease in melanoma
por: Patel, Riyaben P, et al.
Publicado: (2023) -
Obesity and the Impact on Cutaneous Melanoma: Friend or Foe?
por: Smith, Lorey K., et al.
Publicado: (2020) -
Targeting oncogenes in advanced melanoma
por: McArthur, GA
Publicado: (2012) -
CDK4/6 Inhibition Reprograms Mitochondrial Metabolism in BRAF(V600) Melanoma via a p53 Dependent Pathway
por: Santiappillai, Nancy T., et al.
Publicado: (2021) -
Genome-wide RNAi screen for genes regulating glycolytic response to vemurafenib in BRAF(V600) melanoma cells
por: Smith, Lorey K., et al.
Publicado: (2020)